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Abstract
Purpose The purpose of this study was to evaluate the
prevalence of cardiac autonomic neuropathy (CAN) in a
cohort of patients with type 2 diabetes, truly asymptomatic
for coronary artery disease (CAD), using heart rate
variability (HRV) and 123I-metaiodobenzylguanidine
(123I-mIBG) myocardial scintigraphy.
Methods The study group comprised 88 patients with type
2 diabetes prospectively recruited from an outpatient
diabetes clinic. In all patients myocardial perfusion
scintigraphy, CAN by HRV and 123I-mIBG myocardial
scintigraphy were performed. Two or more abnormal tests
were defined as CAN-positive (ECG-based CAN) and one
or fewer as CAN-negative. CAN assessed by 123I-mIBG
scintigraphy was defined as abnormal if the heart-to-
mediastinum ratio was <1.8, the washout rate was >25%,
or the total defect score was >13.
Results The prevalence of CAN in patients asymptomatic
for CAD with type 2 diabetes and normal myocardial
perfusion assessed by HRVand 123I-mIBG scintigraphy was
respectively, 27% and 58%. Furthermore, in almost half of
patients with normal HRV, 123I-mIBG scintigraphy showed
CAN.
Conclusion The current study revealed a high prevalence of
CAN in patients with type 2 diabetes. Secondly, disagree-
ment between HRV and 123I-mIBG scintigraphy for the
assessment of CAN was observed.
Keywords Diabetes . Cardiac autonomic neuropathy .
Heart rate variability . 123I-mIBG scintigraphy
Introduction
Diabetes is an increasing health-care problem [1]. Cardio-
vascular complications including coronary artery disease
(CAD), are the most common causes of mortality and
morbidity in patients with type 2 diabetes [2]. Because
patients with type 2 diabetes often suffer from CAD
without symptoms, risk stratification is needed to identify
patients at high risk of CAD. In the DIAD (detection of
silent myocardial ischemia in asymptomatic diabetic sub-
jects) study the overall prevalence by SPECT of silent
myocardial ischaemia was 22% [3]. Although traditional
risk factors failed to predict silent myocardial ischaemia,
cardiac autonomic neuropathy (CAN) assessed by heart rate
variability (HRV), was a strong predictor of silent myocar-
dial ischaemia in this study. Furthermore, CAN is one of
the most common complications associated with diabetes
and has been associated with an increased risk of mortality
and major cardiovascular events [4]. CAN assessed by
HRV is a sensitive method for detecting neuropathy of the
vagal nerve, characterized by resting tachycardia and
reduced HRV [5]. In addition, sympathetic cardiac inner-
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vation can nowadays be assessed directly and noninva-
sively with 123I-mIBG myocardial scintigraphy in many
clinical disorders, including diabetes [6]. Several previous
studies have evaluated the relationship between HRV and
123I-mIBG myocardial scintigraphy in patients with diabe-
tes [7–9]. However, the current observational study specif-
ically evaluated the prevalence of CAN in patients with
type 2 diabetes and without symptoms of CAD comparing
HRV with 123I-mIBG myocardial scintigraphy.
Methods
Patient population
A total of 155 patients were referred from an outpatient
diabetic clinic to our institution for comprehensive clinical
risk stratification. This comprehensive evaluation included
adenosine stress SPECT myocardial perfusion imaging to
assess myocardial ischaemia, and123I-mIBG myocardial
scintigraphy and HRV to assess CAN. The diagnosis of
diabetes was established by the referring physician and
confirmed by patient history or the use of medication such
as insulin or oral hypoglycaemic agents [10]. Inclusion
criteria consisted of confirmed type 2 diabetes in combina-
tion with complete absence of angina or angina-equivalent
symptoms. Asymptomatic status was confirmed using the
Rose questionnaire for angina [11]. Exclusion criteria were:
known CAD, treatment with antianginal medication, elec-
trocardiographic evidence of Q wave myocardial infarction,
ischaemic ST segment or T wave changes or complete left
bundle branch block and active bronchospasm, excluding
the use of adenosine as stressor for SPECT myocardial
perfusion imaging. For the current analysis, the relationship
between sympathetic dysfunction as assessed by 123I-mIBG
myocardial scintigraphy and the prevalence of CAN as
assessed by HRV was evaluated only in patients with
normal myocardial perfusion (stress and rest).
Adenosine stress SPECT myocardial perfusion imaging
Data acquisition and analysis were performed as described
before [12]. Briefly, ECG-gated SPECT imaging was
performed using a 2-day protocol (adenosine and rest) with
technetium-99m sestamibi (99mTc-MIBI). Twelve-lead elec-
trocardiography (ECG) was recorded each minute and
continuously monitored (leads aVF, V1 and V5) for the
development of arrhythmia or ST-segment deviation.
Imaging was performed as a standardized protocol
120 min after tracer injection, using a triple-head SPECT
camera (GCA 9300/HG; Toshiba, Tokyo, Japan) using low-
energy, high-resolution collimators. Images were acquired
using a circular 360° orbit, 60 projections and 40 s per
projection [13]. No attenuation correction was applied. The
cardiac images were processed and short-axis, horizontal
and vertical long-axis views were reconstructed. The
adenosine stress SPECT myocardial perfusion imaging
studies were clinically read and considered normal under
the following conditions: (1) if both the summed rest score
and the summed difference score were <2, (2) if the resting
LVEF was ≥45%, and (3) in the absence of increased lung
uptake, transient ischaemic dilation or flat or down-sloping
ST-segment depression of ≥1 mm at 80 ms after the J-point
in two or more leads on the ECG during adenosine infusion
[14].
Cardiovascular autonomic reflex tests
Data acquisition
To assess CAN, HRV was measured during the following
four cardiovascular reflex tests and recorded with the aid of
a Holter ECG [15, 16]:
1. HRV at rest over 150 consecutive beats
2. HRV during deep breathing at six cycles per minute
over 120 consecutive beats
3. HRV during Valsalva manoeuvre
4. Immediate heart rate response to standing from the
recumbent position
A final test measured the difference in systolic blood
pressure between supine and upright positions. No patients
were receiving drugs influencing HRV, such as neuroleptic
drugs or clozapine. Antihypertensive medications such as
angiotensin converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARB) were stopped 1 week
before HRV measurements [17].
Data analysis
All Holter ECG recordings were analysed by two experi-
enced observers unaware of the clinical history of the
patients. For the evaluation of HRV at rest, the coefficient
of variation was used [18]. HRV during deep breathing was
evaluated by calculating the E-I ratio (ratio of the mean
longest to shortest R-R interval during inspiration and
expiration, respectively) [19]. The ‘Valsalva ratio’ was
calculated as the ratio of the longest R-R interval following
release to the shortest R-R interval during the manoeuvre
[20]. Immediate heart rate response to standing up was
calculated as the ‘30-15 ratio’, defined as the longest R-R
interval of beats 20–40 divided by the shortest R-R interval
of beats 5–25 with beat one being the first one during the
process of getting up. The shortest R-R interval came
always prior to the longest R-R interval in the calculation of
the 30-15 ratio. Age-related normal ranges were used for
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evaluation of these four cardiovascular reflex tests [21].
Patients were excluded from analysis when either one or
more recordings of HRV during Holter monitoring con-
sisted of too few consecutive beats for interpretation or if
extra systoles impaired interpretation. A decrease in systolic
blood pressure equal to or greater than 30 mmHg within
2 min of standing was defined as an abnormal heart rate
response [22].
Thus, CAN assessed by HRV was classified according to
the number of abnormal cardiovascular reflex tests. Two or
more abnormal tests were defined as CAN-positive (ECG-
based CAN) and one or fewer as CAN-negative [23, 24].
123I-mIBG myocardial scintigraphy imaging protocol
Data acquisition
Tricyclic antidepressant drugs, sympathetic agents, and other
drugs known to interfere with mIBG uptake were withdrawn
1 week before data acquisition. Thyroid uptake of unbound
123I was blocked with sodium iodide solution given orally,
and 60 min later 185 MBq of 123I-mIBG (GE Healthcare) was
injected intravenously over 60 s at rest. Anterior planar
images of the chest were acquired 15 min after injection and
stored in a 256x256 matrix. Thereafter, a 360° SPECT study
was acquired using a double-head gamma camera (GCA
9300/HG; Toshiba, Tokyo, Japan) (4° per step, 35 s per
projection, 128×128 matrix). Repeat planar and SPECT
studies were acquired approximately 4 h after injection. All
camera heads were equipped with low-energy high-resolution
collimators and all acquisitions were performed with a 15%
energy window centred at the 159 keV photopeak of 123I.
Data analysis and image interpretation
Planar images Early (15 min after injection) and late (4 h
delayed) planar images were processed to determine the
heart-to-mediastinum ratio (HMR). The planar 123I-mIBG
images were analysed using regions of interest to calculate
the uptake ratios and washout percentages. A region of
interest was drawn manually over the left ventricle (LV).
The HMR of average counts per pixel was calculated for
the early and delayed images. After correcting for the
physical decay of 123I, early and delayed HMR values were
then used to compute the myocardial washout rate (WR) of
123I-mIBG as follows:
WR ¼ early heart counts early mediastinum counts½ 
 delayed heart counts delayed mediastinum counts½ =
early heart counts early mediastinum counts½   100%:
Since most available evidence supports the use of the
delayed 123I-mIBG (and the derived HMR and WR) for risk
stratification, abnormal delayed HMR and WR were
defined as those values lower than 1.8 and higher than
25%, respectively [6, 25–28].
SPECT images Polar map formats were used for semi-
quantitative interpretation. The delayed myocardial
SPECT images were divided into 17 segments and each
segment was evaluated in consensus by two expert
observers, using a four-point scoring system (0 >70%
tracer uptake, 1 50–70% tracer uptake, 2 30–50% tracer
uptake, 3 <30% tracer uptake) [14]. As a result, the
summed score for each study could theoretically range
from 0 to 51 (17×3). The total defect score (TDS) was
calculated as the sum of all defect scores. The TDS was
converted to percentage of the total denervated myocardi-
um. The percentage denervation in the LV was calculated
as follows: TDS=51 maximum score ¼ 17 3½   100ð .
Based on the study by Kasama et al., a TDS of >18 was
considered abnormal, and in terms of the four-point
scoring system used in the current study, a TDS of >13
would be considered abnormal [26].
Next, the location of defects was evaluated, and
categorized as located inferior, apical, lateral, anterior or
septal. In addition, patients were categorized as having one
defect allocated to one region (see above) or having defects
in two or more regions. Diffusely reduced 123I-mIBG
uptake was defined as abnormal HMR and no clear defect
on the SPECT polar map.
A composite endpoint (HMR<1.8,WR>25%, or TDS >13)
was used to define an abnormal 123I-mIBG study.
Statistical analysis
Categorical baseline characteristics were expressed as
numbers and percentages. Continuous variables were
expressed as means (±standard deviation) and compared
with the two-tailed t test for independent samples.
Statistical analyses were performed using SPSS software,
version 12.0 (SPSS, Chicago, IL) and SAS software (The SAS
system, release 6.12; SAS, Cary, NC). A p-value<0.05 was
considered as statistically significant.
Results
Patient characteristics
Initially 155 patients were referred for risk stratification
including adenosine stress SPECT myocardial perfusion
imaging to assess myocardial ischaemia, and123I-mIBG
myocardial scintigraphy and HRV to assess CAN. Of these
155 patients, 110 (71%) with normal SPECT perfusion
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studies were identified, and of these, 22 (20%) were
excluded because of incomplete datasets (13) or poor 123
I-mIBG image quality (9). Thus, the final patient population
consisted of 88 patients (56 men, age 53±10 years). The
patient characteristics are shown in Table 1. The mean
duration of diabetes was 9.8±8.2 years. Most of the patients
were on oral antidiabetic therapy (61%), 35% were using
ACE inhibitors, and 21% ARB. Complications of diabetes,
such as peripheral neuropathy and/or peripheral vascular
disease, were seen 28 patients.
Cardiac autonomic neuropathy assessed by HRV
CAN was classified according to the number of abnormal
cardiovascular reflex tests. Of the 88 patients, 30 (34%) had
one or more abnormal cardiovascular reflex tests, and 24
(27%) had two or more abnormal tests and were categorized
as CAN-positive.
Cardiac autonomic dysfunction assessed by 123I-mIBG
Of the 88 patients, 37 (42%) had a normal 123I-mIBG study. In
the remaining 51 patients (58%), the 123I-mIBG study was
abnormal. Of these 51 patients, 22 (43%) had one criterion
for an abnormal 123I-mIBG study, and the remaining 29
(57%) had two or more criteria. Of the total 88 patients, 36
(41%) had a HMR of <1.8 (mean 1.62±0.13) and 32 (36%)
had a WR of >25% (mean 34±8). Finally, 25 patients (28%)
had a TDS of >13 (mean 43±18).
Location of 123I-mIBG defects on SPECT
Among the total study population of 88 patients, 49
patients (56%) had defects on SPECT. The distribution of
the location of the defects in the total study population
was as follows: inferior 25%, apex 8%, anterior 3%,
diffuse diminished uptake 9% and two or more regions
10%.
Figures 1 and 2 show the distribution of the location of
the innervation defects in all patients with abnormalities
and in patients with a TDS of >13, respectively. The
majority of the innervation defects (in 22 patients) were
located in the inferior wall. Seven patients showed defects
in the apex, whereas three patients had defects in the
anterior wall. Eight patients had diffuse diminished tracer
uptake over the entire LV and nine patients had defects in
two or more regions. In the 25 patients with a TDS of >13,
the locations of the defects was as follows: inferior wall in
seven patients, apex in four, and two or more regions in six.
Diffused diminished uptake was seen in seven patients.
Table 1 Characteristics of 88 patients with diabetes type 2. Values are











Oral and insulin 11 (13)
Peripheral vascular disease 9 (10)
Peripheral neuropathy 19 (22)
Peripheral vascular and neuropathy 11(13)
Body mass index (kg/m2) 29.2±5.7
Waist circumference (cm) 103±15.0
Hypertension 47 (53)
Hypercholesterolaemia 46 (52)
Family history of CAD 52 (59)
Current smoking 12 (14)
Medication
Aspirin 18 (21)
ACE inhibitors 31 (35)
ARB 18 (21)
Statins 45 (51)
Total cholesterol (mmol/l) 4.9±1.1
Low-density lipoprotein (mmol/l) 3.2±.1.1




Urine albumin/creatinine ratio 12.4±32.8
Chain reactive protein (mg/l) 8.3±5.8
Apolipoprotein A1 (g/l) 1.4±0.30






≥ 2 regions 
Fig. 1 Pie chart showing the location of the innervation defects on
123I-mIBG myocardial scintigraphy
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Cardiac autonomic dysfunction assessed by 123I-mIBG
versus cardiac autonomic neuropathy by HRV
Results of the individual comparisons of HMR, WR and TDS
values between patients with and without CAN as determined
byHRVare presented in Figs. 3, 4 and 5, respectively. Among
patients with normal HRV, 21 (72%) had a HMR of <1.8
(mean 1.66±0.10), 18 (62%) had a WR of >25% (mean 34±
7) and 13 (45%) had a TDS of >13 (mean 26±11). In 15 of
these patients (52%) two or more variables were abnormal.
The agreement and disagreement between HRV and 123I-
mIBG for the assessment of CAN is shown in Fig. 6. Of the
64 patients without CAN by HRV, only 35 (55%) had a
normal 123I-mIBG study. In contrast, almost all patients (22,
92%) with CAN by HRV also had an abnormal 123I-mIBG.
Discussion
In the present study, the prevalence of CAN in patients with
type 2 diabetes, asymptomatic for CAD and with normal
myocardial perfusion, was assessed by HRV and 123I-mIBG
scintigraphy; the prevalence of CAN was 27% by HRV and
58% on 123I-mIBG scintigraphy. Importantly, in almost
50% of patients with normal HRV, 123I-mIBG scintigraphy
showed CAN, suggesting that 123I-mIBG imaging may be
more sensitive for the assessment of CAN than HRV.
CAN is an important complication of diabetes. CAN
results from damage to the autonomic nerve fibres
innervating the heart and blood vessels, which causes
abnormalities in heart rate control and impairs vascular
dynamics. Clinical manifestations of CAN include exercise
intolerance, intraoperative cardiovascular instability, ortho-
static hypotension, asymptomatic ischaemia and painless
myocardial infarction [29]. Furthermore, CAN is associated
with poor outcome related to ventricular arrhythmias and
sudden cardiac death [4, 30]. In clinical practice, it is
possible to assess CAN by measuring HRV. When CAN
has progressed significantly, it may result in a reduction in
HRV [31]. Measuring HRV has been shown to be a simple,
noninvasive method to evaluate the sympatheticovagal
balance at the sinoatrial level, and can identify patients at




≥ 2 regions 
Fig. 2 Pie chart showing the location of the innervation defects on
123I-mIBG myocardial scintigraphy in patients with a TDS of >13








Fig. 3 Box plot showing the distribution of HMR values in patients
with and without CAN as determined by HRV. Average HMR was
significantly higher in patients without CAN (1.89±0.21) than in
patients with CAN (1.72±0.23, p=0.001)
















Fig. 4 Box plot showing the distribution of WR values in patients
with and without CAN as determined by HRV. Average WR was
significantly lower in patients without CAN (18.5%±12.7%) than in
patients with CAN (25.9%±13.5%, p=0.019)










Fig. 5 Box plot showing the distribution of TDS values in patients
with and without CAN as determined by HRV. Average TDS was
significantly lower in patients without CAN (11.2±4.7) than in
patients with CAN (28.8±28.3, p=0.002)
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Therefore, assessing HRV is potentially important in the
management of patients with diabetes. In the current study,
a series of simple bedside tests for detecting CAN were
used [34]. As early as 1976 Ewing et al. reported the results
in 37 diabetic patients with symptoms and clinical features
suggestive of autonomic neuropathy who were followed for
33 months [35]. The authors concluded that simple
autonomic function tests provided significant prognostic
information, with abnormal tests being associated with a
high mortality. These results were confirmed in a larger
population of 605 patients (the Hoorn study) with a follow-
up period of 9 years [4]. Mortality during the follow-up was
17% (101 patients); patients with diabetes and impaired
autonomic function had a twofold mortality risk.
123I-mIBG is an analogue of the false neurotransmitter
guanethidine. It is taken up by adrenergic neurons in a
similar fashion to norepinephrine and does not undergo
intracellular metabolism. Imaging with this agent reflects
uptake in presynaptic neurons as modulated by the
norepinephrine transporter and the status of intraneuronal
storage of norepinephrine [36]. Recently, Nagamachi et al.
investigated retrospectively the long-term (mean 7.2±
3.2 years) prognostic value of 123I-mIBG scintigraphy for
both cardiac events and mortality in 144 patients with type
2 diabetes and normal myocardial perfusion [6]. A
decreased delayed HMR was an independent predictor of
long-term mortality. A combination of 123I-mIBG scintig-
raphy parameters and HRV was independently predictive of
cardiac events.
Previous data have suggested that 123I-mIBG scintigraphy
may be more sensitive than HRV for the detection of CAN
in diabetic subjects [16, 37]. The role of CAN in
asymptomatic diabetic patients has been described by
Valensi et al. [38]. In that study, 75 patients with at least
two cardiovascular risk factors, were evaluated for silent
myocardial ischaemia and CAN with a follow-up period of
3–7 years. Of these patients, 11 (15%) had a major
cardiovascular event, and multivariate analysis demonstrated
that CAN was a better predictor of major cardiac events than
silent myocardial ischaemia. Furthermore, Langer et al.
investigated CAN in relation to HRV and 123I-mIBG
scintigraphy in 23 normal subjects and 65 asymptomatic
patients with diabetes type 2 and silent myocardial ischaemia
[39]. The authors found that 123I-mIBG uptake was largely
diminished in diabetic patients, especially in those with
clinically detectable CAN; moreover, diffuse abnormalities
in 123I-mIBG uptake were observed in patients with silent
myocardial ischaemia.
In the present study, we performed a systematic, head-to-
head comparison between HRVand 123I-mIBG scintigraphy
in 88 patients with type 2 diabetes asymptomatic for CAD
to evaluate the presence of CAN. We included many more
patients than previous studies, but although the inclusion
criteria were different, our results are in line with those of
previous studies showing that 123I-mIBG scintigraphy
identified a significantly higher proportion of patients with
CAN than HRV [16, 40, 41]. The fact that more patients
exhibit abnormalities in 123I-mIBG imaging as compared to
HRV underscores the suggestion that abnormalities in
cardiac sympathetic innervation occur prior to ECG-based
(HRV) cardiac autonomic dysfunction [16]. An alternative
explanation is that 123I-mIBG scintigraphy mainly reflects
sympathetic innervation, whereas HRV may be more
related to parasympathetic function [42]. It remains to be
determined which of these two parameters is more useful in
predicting long-term outcome.
While HRV and other traditional parameters provide an
impression of global innervation abnormalities, 123I-mIBG
scintigraphy with SPECT provides information on regional
innervation. The findings of the current study indicate that
regional abnormalities occur often in patients with asymp-
tomatic diabetes. Other studies using 123I-mIBG scintigra-
phy in populations with various cardiovascular diseases
have also shown regional innervation abnormalities [16, 40,
41, 43]. For example, Langer et al. evaluated 65 diabetic
patients and noted significantly impaired 123I-mIBG uptake
in the inferior wall and apex [39]. Additional studies have
shown that abnormalities in CAN tend to occur first in the
inferior regions of the myocardium and then progressively
spread to adjacent segments [44, 45].
Clinical implications
Of all established diabetes-related and cardiac risk factors
in patients with asymptomatic diabetes, poor glycaemic
control is of great importance in the development and
progression of CAN [37, 44]. Accordingly, early detection






















Fig. 6 Agreement and disagreement between HRV and 123I-mIBG
scintigraphy for the assessment of CAN
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current study, 123I-mIBG scintigraphy appears more sensi-
tive than HRV for the detection of CAN in asymptomatic
diabetic patients without myocardial perfusion abnormali-
ties. Identification of these patients may permit risk factor
modification and intensive medical treatment aiming at
better glycaemic control, which in turn may favourably
affect outcome [46–49]. Indeed, several studies have shown
that improvement in CAN (as evidenced by HRV) can be
achieved by weight loss and regular exercise [50, 51].
Furthermore, progression of CAN can also be delayed by
intensive medical therapy, thereby reducing the risk of
premature mortality [52].
Limitations
The current study included only diabetic patients, and no
control population was available. Precise threshold values
for diabetic patients and normal controls need to be further
explored for the individual 123I-mIBG variables (HMR, WR
and TDS) to define CAN, and these cut-off values may be
dependent on patient demographics and acquisition. More-
over, the variation in the individual values appears to be
substantial and the use of a composite endpoint to define an
abnormal 123I-mIBG study may be preferred.
Conclusion
The poor long-term prognosis in asymptomatic diabetic
patients with CAN justifies early risk stratification. In the
current head-to-head comparison between 123I-mIBG scin-
tigraphy and HRV, 123I-mIBG scintigraphy identified
significantly more patients with CAN than HRV. These
findings suggest that 123I-mIBG myocardial scintigraphy
may be suited to early detection of CAN. However, the
current limitations in defining imaging abnormalities in
diabetic patients need to be considered and more data are
clearly needed.
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